GadoSpin™ D is a dendritic MRI contrast agent specifically designed for dynamic contrast-enhanced (DCE) studies of vascular integrity and angiogenesis. Incorporating 24 gadolinium ions within a globular dendrimer structure, it provides controlled extravasation in fenestrated vasculature of tumors and inflamed tissues while remaining confined in intact vessels.
Left:DCE-MRI-based tumor therapy monitoring using GadoSpin D. The effect of anti-angiogenic treatment in mice is studied as contrast agent uptake in regions of tumor angiogenesis. Comparing T1-weighted pre- and post-contrast scans, the contrast effect appears to be significantly lower (and restricted to the cortex region) in treated mice as compared to control mice. This can be attributed to a treatment-induced reduction of neovasculature.
Right:Schematic representation of DCE-MRI using GadoSpin D. Tumor tissue exhibits a significantly higher extravasation of the agent than the reference muscle tissue. Temporal sampling allows for exact quantification and calculation of exchange rate constants.
GadoSpin™ D is suitable for quantification of angiogenesis, evaluation of vascular abnormalities in tumors and inflammation, and assessment of therapeutic efficacy in preclinical models. Its blood pool effect additionally allows for MR angiography as an alternative to polymeric agents such as GadoSpin P.
Relaxivity at 37 °C and 1.5 T is r1 = 19 L mmol-1 s-1 and r2 = 29 L mmol-1 s-1 in plasma, and r1 = 17 L mmol-1 s-1 and r2 = 22 L mmol-1 s-1 in water. The agent has an intermediate molecular weight of approximately 17,000 g mol-1. These properties support stable vascular retention and controlled extravasation for DCE-MRI studies.
Schematic diagram of GadoSpin D:
The dendritic design of GadoSpin™ D enables reproducible assessment of vascular permeability and angiogenesis. Temporal sampling allows precise quantification of exchange rate constants, while the agent’s confined circulation in intact vasculature ensures consistent imaging and longitudinal study capability.
In tumor models, DCE-MRI with GadoSpin™ D effectively monitors therapy response by comparing pre- and post-contrast T1-weighted scans. Treated tumors show reduced and spatially restricted contrast enhancement relative to control tumors, reflecting diminished neovasculature. The agent enables exact measurement of extravasation differences between tumor and reference tissue.
GadoSpin™ D is available in single or multiple injection packs. Ordering through an authorized distributor ensures access to technical support, local availability, and guidance for preclinical DCE-MRI protocols.
Authorized distributor of Viscover products by Nanopet Pharma GmbH. This page contains original distributor-specific content supporting preclinical vascular and angiogenesis imaging using GadoSpin™ D.
Price range: USD $719 through USD $3,329
